%0 Journal Article
%T Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers
%A Antonella Dal Mas
%A Enrico Ricevuto
%A Eugenio Ciacco
%A Francesco Pepe
%A Gemma Bruera
%A Giancarlo Troncone
%A Giuseppe Calvisi
%A Maurizio Simmaco
%A Silvia Massacese
%A Umberto Malapelle
%J Archive of "Therapeutic Advances in Medical Oncology".
%D 2019
%R 10.1177/1758835919846421
%X Intensive triplet chemotherapy/bevacizumab significantly increased metastatic colorectal cancer (MCRC) outcome. This phase II study investigated the safety/activity of FIr-C/FOx-C triplet/cetuximab (CET) in first-line RAS wild-type and the prediction of individual limiting toxicity syndromes (LTS) by pharmacogenomic biomarkers
%K FIr-C/FOx-C triplet chemotherapy plus cetuximab
%K first line
%K metastatic colorectal cancer
%K phase II study
%K RAS wildtype
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535746/